Abciximab exerts its antiplatelet effect through which mechanism?
- A Monoclonal antibody Fab fragment binding the glycoprotein IIb/IIIa receptor, blocking fibrinogen-mediated platelet aggregation ✓
- B Irreversible blockade of the ADP receptor P2Y12
- C Phosphodiesterase-3 inhibition raising intraplatelet cAMP
- D Thromboxane A2 receptor antagonism
Correct answer: A. Monoclonal antibody Fab fragment binding the glycoprotein IIb/IIIa receptor, blocking fibrinogen-mediated platelet aggregation
Explanation
Abciximab is the Fab fragment of a chimeric human-murine monoclonal antibody directed against glycoprotein IIb/IIIa, the final common pathway of platelet aggregation where fibrinogen cross-links activated platelets. Blocking it prevents aggregation regardless of the agonist involved. Option B describes thienopyridines, option C describes cilostazol and dipyridamole, and option D describes agents such as picotamide. Its notable adverse effects are acute thrombocytopenia and bleeding.
Reference: Katzung Basic and Clinical Pharmacology, 15th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.